Pure Global
NCT04569032

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
Seagen Inc.·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
brentuximab vedotin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Seagen Inc.
Location
Birmingham,Stanford,Aurora,Aurora,Washington,Niles,New Orleans,New Orleans,Ann Arbor,New York,Cleveland,Fairfield,Knoxville,Amarillo,Austin,Fort Worth,Houston,Longview,Richmond,Virginia Beach,Cedex 9,, France,Italy,Spain,United Kingdom,United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Nov 12, 2020
End date
Dec 31, 2023
Enrollment
80 participants
Primary outcome

Objective response rate (ORR) per blinded independent central review (BICR) using Revised Response Criteria for Malignant Lymphoma criteria (Cheson 2007)

Summary

This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for
 people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out
 what side effects occur when brentuximab vedotin and CHP are used together. A side effect is
 anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three
 drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat
 certain types of PTCL.

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04569032
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04569032 through Pure Global AI's free database. This Phase 2 trial is sponsored by Seagen Inc. and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.